Immunizations - childhood
Exam Tips
- Know key UK ages: 8, 12, 16 weeks; 1 year; 18 months (eligible cohorts); 3 years 4 months; 12-13 years; and school year 9 boosters.
- Live vaccine safety is a common OSCE station: check immunosuppression status and SCID result before rotavirus.
- MenB visits commonly cause fever in infants; examiners like specific counselling including prophylactic paracetamol dosing.
- If a child is acutely unwell after vaccination, assess for serious infection first; temporal association is not proof of adverse reaction.
- Catch-up principles are high yield: do not restart whole courses unnecessarily, continue from valid previous doses using minimum intervals.
Definition
The UK childhood immunization programme is a structured schedule of active immunization from infancy to adolescence designed to prevent severe, transmissible infections such as meningococcal disease, measles, pertussis, Hib, pneumococcal disease, and HPV-related malignancy. In clinical practice it is both an individual intervention (reducing morbidity and mortality) and a population strategy (maintaining herd protection and preventing resurgence of previously controlled infections).
Pathophysiology
Vaccines present antigen (live attenuated organisms, inactivated components, toxoids, recombinant proteins, polysaccharide-protein conjugates, or mRNA/vector platforms depending on product) to induce adaptive immune responses with immune memory. Conjugate vaccines (for example Hib and pneumococcal conjugate) convert a T-cell-independent polysaccharide response into a T-cell-dependent response, improving infant immunogenicity and memory. Booster doses drive affinity maturation and longer protection as maternal antibody wanes and exposure risk rises with age; high coverage also reduces carriage/transmission for some pathogens, lowering community disease burden.
Risk Factors
- Incomplete or delayed vaccination (missed appointments, access barriers, vaccine hesitancy)
- Immunosuppression (affects suitability of live vaccines such as rotavirus, MMRV, LAIV)
- Asplenia or complement deficiency (higher risk of invasive meningococcal and pneumococcal disease)
- Chronic cardiorespiratory, renal, liver, neurologic, or metabolic disease (higher influenza and invasive infection risk)
- Household/travel exposure to regions with higher prevalence of vaccine-preventable infections
- Very young age before full primary course completion
Clinical Features
Symptoms
- Usually well and asymptomatic at routine immunization visits
- Mild post-vaccine fever, irritability, reduced feeding, and local tenderness can occur
- Post-MMRV/varicella-containing vaccines: transient mild rash or fever may occur several days later
- If unvaccinated and infected, symptoms depend on pathogen (for example fever/rash in measles, cough/paroxysms in pertussis, neck stiffness/photophobia in meningitis)
Signs
- Injection-site erythema, swelling, or pain (typically self-limiting)
- Normal examination at pre-vaccination assessment in most children
- Red flags requiring urgent assessment rather than routine vaccination: toxic appearance, shock, meningism, stridor/airway compromise
- Anaphylaxis signs post-immunization are rare but include wheeze, hypotension, and urticaria
Investigations
Management
Lifestyle Modifications
- Use every clinical contact to check immunization status and offer catch-up
- Provide parent-centered counselling on benefits, common adverse effects, and safety-net advice
- Record batch number, site, route, and timing; ensure recall/reminder systems are active
- Advise annual influenza vaccination in eligible children during each season
- See Figure: UK routine childhood immunization timeline (age-based schedule chart used in clinic teaching)
Pharmacological Treatment
Routine infant primary/booster immunization
- DTaP/IPV/Hib/HepB (Infanrix hexa or Vaxelis) 0.5 mL IM at 8, 12, 16 weeks; additional dose at 18 months for children born on/after 1 July 2024
- MenB (Bexsero) 0.5 mL IM at 8 weeks, 12 weeks, and 1 year
- Rotavirus (Rotarix) 1.5 mL oral at 8 and 12 weeks
- PCV (Prevenar 13) 0.5 mL IM at 16 weeks and 1 year
- MMRV (ProQuad or Priorix-Tetra) 0.5 mL SC (or IM per product) from 1 year per current UK rollout criteria
Do not give live vaccines in severe immunosuppression; postpone vaccination in acute severe febrile illness (minor infection is not a contraindication). Rotavirus is contraindicated in SCID and previous intussusception. Previous anaphylaxis to a vaccine/component is a contraindication to further doses of that product.
Pre-school and adolescent programme
- DTaP/IPV (REPEVAX) 0.5 mL IM at 3 years 4 months
- MMRV booster (ProQuad or Priorix-Tetra) 0.5 mL at 3 years 4 months
- HPV (Gardasil 9) 0.5 mL IM at 12-13 years (usually single-dose schedule in immunocompetent adolescents; follow current national schedule for exceptions)
- Td/IPV (REVAXIS) 0.5 mL IM at around 14 years (school year 9)
- MenACWY (Nimenrix, Menveo, or MenQuadfi) 0.5 mL IM at around 14 years; catch-up available up to age 25 in eligible cohorts
Check vaccine history before teenage boosters; complete missing MMR/MMRV as catch-up. In those with uncertain varicella history, follow local programme advice. Observe for immediate adverse reactions after administration.
Seasonal influenza prevention and antipyresis support
- LAIV (Fluenz) 0.2 mL intranasal annually (0.1 mL per nostril) in eligible children
- Inactivated influenza vaccine 0.5 mL IM annually when LAIV is unsuitable/contraindicated
- Paracetamol prophylaxis with MenB-containing infant appointments: 60 mg oral (for example 2.5 mL of 120 mg/5 mL suspension) at vaccination, then 60 mg at 4-6 hours, then 60 mg 4-6 hours later
LAIV is contraindicated in severe immunosuppression and generally avoided with salicylate therapy. Give clear fever-management advice after MenB. Escalate urgently if persistent high fever, non-blanching rash, breathing difficulty, or reduced responsiveness.
Complications
- Outbreaks of measles, pertussis, or meningococcal disease in under-immunized groups
- Severe invasive infection (meningitis, sepsis, epiglottitis, pneumonia) with potential death or disability
- Disease-specific sequelae such as hearing loss after meningitis, encephalitis after measles, or chronic liver disease from hepatitis B
- Rare vaccine adverse events (for example anaphylaxis, febrile seizures, intussusception after rotavirus) requiring urgent recognition and reporting
Prognosis
With timely completion of the UK schedule, prognosis at population level is excellent, with major reductions in incidence, complications, and deaths from multiple childhood infections. Individual prognosis worsens when doses are delayed or missed, especially in infancy when risk of invasive disease is highest; catch-up vaccination substantially mitigates this risk.
Sources & References
✅NICE Guidelines(1)
- Immunizations - childhood[overview]
📖Textbook References(2)
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 706)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 706)[context]